<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="34716">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02654639</url>
  </required_header>
  <id_info>
    <org_study_id>2015-0959</org_study_id>
    <nct_id>NCT02654639</nct_id>
  </id_info>
  <brief_title>Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer</brief_title>
  <acronym>ALEXANDRIA</acronym>
  <official_title>An Open-Label, Multi-center, Phase 2 Study of Switch Maintenance With TAS-102 Plus Bevacizumab Following Oxaliplatin or Irinotecan-Based Fluoropyrimidine-Containing Induction Chemotherapy in Patients With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II study of TAS-102 plus bevacizumab switch maintenance therapy in patients with mCRC
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Drug:

      TAS-102 (trifluridine and tipiracil hydrocholoride) and bevacizumab

      Dosing Details:

      Starting dose of TAS-102 is 35 mg/m2 administered orally twice daily, after meals, for 5
      days a week with 2 days rest for 14 days, followed by 14 days rest (1 treatment cycle).

      Bevacizumab 5 mg/kg intravenously every 14 days. The treatment cycle repeats every 28 days.
      Patients may take TAS-102 plus bevacizumab until they exhibit progression of disease,
      withdraw consent, or experience unacceptable toxicity.This is a single arm study. All
      patients receive the same study treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>TAS-102 and Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral TAS-102 and intravenous Bevacizumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAS-102 and Bevacizumab</intervention_name>
    <description>TAS-102 Twice a day by mouth day 1-5 and 8-12 and Bevacizumab by intravenous infusion once every 14 days</description>
    <arm_group_label>TAS-102 and Bevacizumab</arm_group_label>
    <other_name>Lonsurf</other_name>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Written informed consent

          -  Histologically proven, unresectable, evaluable metastatic colorectal cancer

          -  16 to 20 weeks of first-line therapy with oxaliplatin, and/or irinotecan-based
             flourorpyrimidine-containing chemotherapy plus Bevacizumab

          -  Patients must have stable disease (or better) during the initial induction
             chemotherapy with first-line chemotherapy.

          -  No progressive disease at the time of initiation of maintenance therapy

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1

          -  Adequate organ and marrow function

          -  Women of child-bearing potential and men must agree to avoid pregnancy

          -  Patient must start maintenance therapy at least 14 days after the last administered
             induction chemotherapy but no later than 30 days.

        Exclusion Criteria

          -  Patients whose tumors have progressed on first-line treatment

          -  Patients with active concurrent malignancy, other than superficial, non-invasive
             squamous cell carcinoma of the skin or uterine cervix, within the past three years.

          -  Women who are pregnant or lactating

          -  Unstable heart disease

          -  Uncontrolled active infection requiring antibiotics within one week prior to first
             dose.

          -  Patients with active CNS malignancy.

          -  Persistent protein in the urine

          -  Patients with bowel obstruction or uncontrolled vomiting.

          -  Patients with serious psychiatric or medical conditions that could interfere with
             treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Salem, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Georgetown University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Holly DiFebo, BSN</last_name>
    <phone>202-687-6974</phone>
    <email>kd252@georgetown.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisa Ley, MSN</last_name>
    <phone>202-687-6653</phone>
    <email>leyl@georgetown.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 30, 2017</lastchanged_date>
  <firstreceived_date>January 8, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic Colorectal Cancer</keyword>
  <keyword>Advanced Colorectal Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Trifluridine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
